Pfizer Just Raised Its 2026 Guidance -- but the Boost Leans Heavily on a Drug Running Out the Patent Clock

Why it matters

Pfizer raising its 2026 guidance based on a drug nearing patent expiration is routine corporate earnings news with limited direct impact on credit markets or underwriting standards.

Sources

• The Motley Fool

  Pfizer Just Raised Its 2026 Guidance -- but the Boost Leans Heavily on a Drug Running Out the Patent Clock

  This problem has a solution, and Pfizer is implementing it.

• Nasdaq

  Pfizer Just Raised Its 2026 Guidance -- but the Boost Leans Heavily on a Drug Running Out the Patent Clock

  Key PointsPfizer still relies somewhat heavily on Eliquis, a medicine that will lose patent exclusivity relatively soon.